.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA03_LevodopaDecarboxylaseInhibitorAn.LevodopaDecarboxylaseInhibitorAn .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BA03_LevodopaDecarboxylaseInhibitorAn.LevodopaDecarboxylaseInhibitorAn| name: | LevodopaDecarboxylaseInhibitorAndComtInhibitor |
| ATC code: | N04BA03 | route: | oral |
| n-compartments | 2 |
A combination therapy for Parkinson's disease consisting of levodopa, a dopamine precursor, administered with a dopa decarboxylase inhibitor (such as carbidopa or benserazide) to prevent peripheral conversion of levodopa to dopamine, and a catechol-O-methyltransferase (COMT) inhibitor (such as entacapone or tolcapone) to further prolong levodopa's plasma half-life. This combination is widely used and approved for managing motor symptoms in Parkinson's disease.
Pharmacokinetic parameters for adult patients with Parkinson's disease, co-administered orally as levodopa/carbidopa/entacapone fixed-dose formulation.
Rouru, J, et al., & Scheinin, M (1999). Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. European journal of clinical pharmacology 55(6) 461–467. DOI:10.1007/s002280050657 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10492060
Scott, LJ (2016). Opicapone: A Review in Parkinson's Disease. Drugs 76(13) 1293–1300. DOI:10.1007/s40265-016-0623-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498199